|
|
Blood, 15 December 2003, Vol. 102, No. 13, pp. 4499-4503.
Prepublished online as a Blood First Edition Paper on July 24, 2003; DOI 10.1182/blood-2003-01-0083.
 Previous Article | Table of Contents | Next Article 
NEOPLASIA
Overexpression of P-glycoprotein in K562 cells does not confer resistance to the growth inhibitory effects of imatinib (STI571) in vitro
Petranel T. Ferrao,
Michelle J. Frost,
Shoo-Peng Siah, and
Leonie K. Ashman
From the Experimental Oncology Unit, School of Biomedical Sciences, University of Newcastle, Callaghan, New South Wales 2308, Australia; and Hunter Medical Research Institute, New South Wales, Australia.
Elevated expression of multidrug efflux pumps such as P-glycoprotein (Pgp) have been associated with resistance to cytotoxic drugs used in the treatment of leukemias and other cancers. Imatinib mesylate (STI-571 or Gleevec) is a potent inhibitor of the BCR/ABL and c-KIT tyrosine kinases. It has displayed considerable efficacy in treatment of patients with Philadelphia-positive acute lymphoblastic leukemia and chronic myelogenous leukemia and those with gastrointestinal stromal tumors (GISTs). However, recently imatinib-resistant relapse has emerged as a significant problem. Although a major cause of resistance appears to be point mutation in the kinase domain of the target enzyme, the potential contribution of elevated multidrug efflux activity has not been systematically evaluated. The imatinib-sensitive human leukemic cell line K562, which is dependent on the activity of BCR/ABL for survival and growth, provides a convenient system for evaluating modulation of drug activity. By expressing Pgp at high levels in these cells, we have demonstrated that this pump provides minimal protection against cell growth inhibition and apoptosis induced by imatinib. In contrast, overexpression of Bcl-xL, which blocks apoptosis, resulted in partial protection against the drug. We conclude that Pgp up-regulation is not likely to be a significant contributor to imatinib resistance. (Blood. 2003;102:4499-4503)
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
Y.-Y. Kuo and Z.-F. Chang
GATA-1 and Gfi-1B Interplay To Regulate Bcl-xL Transcription
Mol. Cell. Biol.,
June 15, 2007;
27(12):
4261 - 4272.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Kuroda, H. Puthalakath, M. S. Cragg, P. N. Kelly, P. Bouillet, D. C. S. Huang, S. Kimura, O. G. Ottmann, B. J. Druker, A. Villunger, et al.
Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic
PNAS,
October 3, 2006;
103(40):
14907 - 14912.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Baccarani, G. Saglio, J. Goldman, A. Hochhaus, B. Simonsson, F. Appelbaum, J. Apperley, F. Cervantes, J. Cortes, M. Deininger, et al.
Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet
Blood,
September 15, 2006;
108(6):
1809 - 1820.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. L. White, V. A. Saunders, P. Dang, J. Engler, A. C. W. Zannettino, A. C. Cambareri, S. R. Quinn, P. W. Manley, and T. P. Hughes
OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib
Blood,
July 15, 2006;
108(2):
697 - 704.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Theou, S. Gil, A. Devocelle, C. Julie, A. Lavergne-Slove, A. Beauchet, P. Callard, R. Farinotti, A. Le Cesne, A. Lemoine, et al.
Multidrug Resistance Proteins in Gastrointestinal Stromal Tumors: Site-Dependent Expression and Initial Response to Imatinib
Clin. Cancer Res.,
November 1, 2005;
11(21):
7593 - 7598.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Deininger, E. Buchdunger, and B. J. Druker
The development of imatinib as a therapeutic agent for chronic myeloid leukemia
Blood,
April 1, 2005;
105(7):
2640 - 2653.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Thomas, L. Wang, R. E. Clark, and M. Pirmohamed
Active transport of imatinib into and out of cells: implications for drug resistance
Blood,
December 1, 2004;
104(12):
3739 - 3745.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Ozvegy-Laczka, T. Heged""s, G. Varady, O. Ujhelly, J. D. Schuetz, A. Varadi, G. Keri, L. Orfi, K. Nemet, and B. Sarkadi
High-Affinity Interaction of Tyrosine Kinase Inhibitors with the ABCG2 Multidrug Transporter
Mol. Pharmacol.,
June 1, 2004;
65(6):
1485 - 1495.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
